MindMed (NASDAQ: MNMD)

Currency in USD

Last close As at 04/12/2023

USD3.30

0.06 (1.85%)

Market capitalisation

USD130m

MindMed is a US clinical-stage biopharmaceutical company leveraging novel psychedelic medicines to target mental health conditions. The company has programs for the treatment of conditions such as generalized anxiety disorder, attention deficit hyperactivity disorder, autism spectrum disorder and opioid use disorder.

Latest Insights

Healthcare | edison tv

MindMed update on major depressive disorder data: Rob Barrow, CEO

Healthcare | edison tv

MindMed – executive interview with Dan Karlin, CMO

Healthcare | edison tv

MindMed – executive interview with Rob Barrow, CEO

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Key Management

  • Maxim Jacobs

    Vice President of Investor Relations and Corp

  • Robert Barrow

    CEO

  • Schond Greenway

    CFO

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 31.2 (16.5) 20.0
Relative 18.7 (17.5) 4.4
52 week high/low US$4.9/US$2.1

Research

cell DNA double helix

thematic

Healthcare

Cell and gene therapies

thematic

Healthcare

Drug delivery platforms

thematic

Healthcare

Neuroscience comeback

thematic

Consumer

IPO apocalypse

thematic

Healthcare

Oncology ABCs (part two) – vaccines: niche no longer

thematic

TMT

ESG, moving beyond the box tick

thematic

Healthcare

Artificial intelligence in drug discovery

thematic

Healthcare

Edison Exhibits- antibiotic development

thematic

Healthcare

The next wave in AMD

thematic

Healthcare

Cannabinoid Therapies- The coming retail wave

thematic

Healthcare

Cannabinoid Therapies- Therapeutics turning a corner

thematic

Healthcare

Drug pricing – Market access and reimbursement

thematic

Healthcare

The diagnostics sector

thematic

Healthcare

ASCO 2017

thematic

Consumer

Deutsche Börse Eigenkapitalforum 2014 Research Guide

thematic

Energy & Resources

ASX Spotlight Conference – London, 6 March 2014

thematic

Energy & Resources

ASX Small to Mid Caps Conference – London, 7 March 2013

thematic

Healthcare

Edison healthcare quarterly: Boom times for US biotech

thematic

Healthcare

Edison healthcare quarterly: Crisis? What crisis?